Blueprint Medicines

Blueprint Medicines company information, Employees & Contact Information

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including systemic mastocytosis and chronic urticaria, breast cancer and other solid tumors. Patients are at the center of our mission. We know that in order to make a difference in their lives, we must create an environment where our employees — also known as the Blue Crew — can do their best work. Our culture of transparency, curiosity and diversity empowers us to draw upon a wide range of backgrounds and perspectives to build a conscientious team dynamic. Ideas come from every member of the Blue Crew, from the executive team to new hires. Each day, our teams commit to approach one another with respect and trust: a simple promise that fosters an inclusive and collaborative spirit. We care deeply about the communities where we live and work, and we strive to make a profound impact where it matters most. Learn more about who we are and explore our career opportunities at https://www.blueprintmedicines.com/careers/. Read our community guidelines: https://www.blueprintmedicines.com/community-guidelines/.

Company Details

Employees
795
Founded
-
Address
45 Sidney St, Cambridge,massachusetts 02139,united States
Phone
617-374-7580
Email
me****@****nes.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge, Massachusetts
Looking for a particular Blueprint Medicines employee's phone or email?

Blueprint Medicines Questions

News

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PR Newswire

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses PR Newswire

Press Release: Sanofi to acquire Blueprint Medicines, - GlobeNewswire

Press Release: Sanofi to acquire Blueprint Medicines, GlobeNewswire

Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire

Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance PR Newswire

Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma - Sixth Street

Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma Sixth Street

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results - PR Newswire

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results PR Newswire

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth - PR Newswire

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth PR Newswire

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting - PR Newswire

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting PR Newswire

Blueprint Medicines to Present at Upcoming Investor Conferences - PR Newswire

Blueprint Medicines to Present at Upcoming Investor Conferences PR Newswire

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance PR Newswire

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) - PR Newswire

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) PR Newswire

Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire

Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance PR Newswire

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress - PR Newswire

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress PR Newswire

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance PR Newswire

Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022 - PR Newswire

Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022 PR Newswire

Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference - PR Newswire

Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire

Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis - PR Newswire

Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis PR Newswire

Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting - PR Newswire

Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting PR Newswire

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting - PR Newswire

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire

Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis - PR Newswire

Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis PR Newswire

Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China - PR Newswire

Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China PR Newswire

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis - PR Newswire

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis PR Newswire

Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies - PR Newswire

Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies PR Newswire

Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche - PR Newswire

Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche PR Newswire

Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors - PR Newswire

Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors PR Newswire

Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics - PR Newswire

Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics PR Newswire

Blueprint Medicines Completes Acquisition of Lengo Therapeutics - PR Newswire

Blueprint Medicines Completes Acquisition of Lengo Therapeutics PR Newswire

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting - PR Newswire

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting PR Newswire

Blueprint Medicines Announces CEO and Leadership Transition Plan - PR Newswire

Blueprint Medicines Announces CEO and Leadership Transition Plan PR Newswire

Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer - PR Newswire

Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer PR Newswire

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis - PR Newswire

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis PR Newswire

Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors - PR Newswire

Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors PR Newswire

Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST - PR Newswire

Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST PR Newswire

FDA Approves Avapritinib for Indolent Systemic Mastocytosis - OncLive

FDA Approves Avapritinib for Indolent Systemic Mastocytosis OncLive

Avapritinib Leads a Charge of Novel Targeted Therapies for Indolent Systemic Mastocytosis - OncLive

Avapritinib Leads a Charge of Novel Targeted Therapies for Indolent Systemic Mastocytosis OncLive

CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma - PR Newswire

CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma PR Newswire

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China - PR Newswire

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China PR Newswire

NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis - PR Newswire

NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis PR Newswire

Blueprint Medicines Appoints Habib Dable to its Board of Directors - citybiz

Blueprint Medicines Appoints Habib Dable to its Board of Directors citybiz

Ayvakit Approved for Indolent Systemic Mastocytosis - Medical Professionals Reference

Ayvakit Approved for Indolent Systemic Mastocytosis Medical Professionals Reference

FDA Lifts Partial Hold on VELA Trial Evaluating BLU-222 in Advanced Solid Tumors - OncLive

FDA Lifts Partial Hold on VELA Trial Evaluating BLU-222 in Advanced Solid Tumors OncLive

Blueprint Medicines Acquires Lengo Therapeutics - citybiz

Blueprint Medicines Acquires Lengo Therapeutics citybiz

Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer - PR Newswire

Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer PR Newswire

Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors - Frontiers

Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors Frontiers

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data - BMC Cancer

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data BMC Cancer

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor - CNN

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor CNN

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis (2023-05-22) - Seeking Alpha

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis (2023-05-22) Seeking Alpha

A precision therapy against cancers driven by KIT/PDGFRA mutations - Science | AAAS

A precision therapy against cancers driven by KIT/PDGFRA mutations Science | AAAS

Top Blueprint Medicines Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant